IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

IN8bio, Inc. (Nasdaq: INAB) is a clinical-stage biopharmaceutical company that specializes in developing innovative gamma-delta T cell therapies. The company’s CEO and Co-founder, William Ho, will be presenting at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference on Thursday, April 18th at 12:30pm ET.

During the conference, there will be a fireside style Q&A session where attendees can ask questions. Those interested in viewing the live presentation can register for the event. Additionally, the management team at IN8bio will be hosting one-on-one meetings with registered, qualified investor attendees. To schedule a meeting, interested parties should contact their Noble representative.

IN8bio’s lead program, INB-400, is currently in a Phase 2 trial for glioblastoma multiforme (GBM). The company also has Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation.

Noble Capital Markets, Inc. is a research-driven investment bank that has been supporting small and microcap companies since 1984. They provide institutional-quality equity research, merchant and investment banking, and order execution services. Noble also hosts the NobleCon investor conference and operates Channelchek, an investor community dedicated to public small and micro-cap companies.

For more information about IN8bio and their immunotherapy programs, visit their website at www.IN8bio.com.